IN YOUR HANDS SHE HAS ONE THING LESS TO FEAR FROM CANCER

As a palliative carer, you know how widely the emotional and physical needs of cancer patients vary. No two are the same. Each one relies on your experience to help maintain their comfort and dignity.

Inevitably though, virtually all patients have one thing in common - the onset of severe pain.

Oral morphine is the mainstay of effective pain control. The Oramorph range of liquids and tablets provides all you need for oral morphine treatment:

- to find the optimum dose – fast acting Oramorph Liquid
- for simple b.d. maintenance – long acting Oramorph SR tablets
- to control breakthrough pain – easy to use Oramorph UDVs

With the Oramorph range, removing the fear of severe pain for most patients is firmly in your hands.

Working together to beat cancer pain

CONTRA-INDICATIONS: respiratory depression, obstructive airways disease, known morphine sensitivity, acute hepatic disease, acute abdomen, paralytic ileus, acute alcoholism, head injuries, coma, raised intracranial pressure, concurrent administration of MAOIs or within 2 weeks of their discontinuation, heart failure secondary to chronic lung disease.

PRECAUTIONS: the first 24 hours post-operatively; hypothyroidism; myocardial; reduced respiratory reserve; chronic hepatic or renal disease; adenocortical insufficiency; prostatic hypertrophy; shock; obstructive bowel disorders; convulsive disorders; myocardial ischaemia; pregnancy, labour, and breast-feeding mothers. Warn patients not to drive or operate dangerous machinery after taking Oramorph. Tolerance and dependence may occur. The depressant effects of morphine are enhanced by other CNS depressants. By reducing gastro-intestinal motility morphine may affect concurrent oral medication. SIDE EFFECTS: Nausea, vomiting, constipation, diarrhoea, confusion, dry mouth, sweating, facial flushing, vertigo, bradycardia, palpitations, orthostatic hypotension, hyperthermia, restlessness, changes of mood, miosis, difficulty in micturition, urticaria or bluish skin, an antidiuretic effect, raised intracranial pressure.

PACK SIZES, LEGAL INFORMATION AND NHS PRICES: Oramorph Oral Solution CD in POM PL0015/0122 100ml £2.31; 250ml £5.36; 500ml £9.70; Oramorph SR Tablets POM CD in POM PL0015/0125 20mg £5.47; 120mg £24.15 UDVs Packs of 25 packs of 10mg CD in POM PL0015/0157; 30mg CD POM £9.30 PL0015/0158; 100mg CD POM £31.00 PL0015/0159; SR Tablets POMCD. 60 tablet packs 10mg £15.95 PL0015/0208; 30mg £23.80 PL0015/0209; 60mg £26.89 PL0015/0210; 100mg £42.59 PL0015/0211.

PRODUCT LICENCE HOLDER: Boehringer Ingelheim, Beesfield Avenue, Bracknell, RG12 8YS. For full prescribing information please see data sheet.

Date of preparation: April, 1996.

Further information is available from: Boehringer Ingelheim Limited, Hospital Division, Beesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: 01344 424600. Date of preparations: December, 1996.

BHDAP73